Ponte J, Ponath P, Gulati R, et al. Enhancement of Humoral and Cellular Immunity with an Anti-Glucocorticoid-Induced Tumour Necrosis Factor Receptor Monoclonal Antibody. Immunology. 2010 Feb. [ahead of print]

Hale G, Rebello P, Al Bakir I, et al. Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes. J Clin Pharmacol. 2010 Feb 10. [Epub ahead of print]

Wiczling P, Rosenzweig M, Vaickus L, Jusko WJ. Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects with Psoriasis and With Type 1 Diabetes Mellitus. J Clin Pharmacol. 2009 Nov 23. [Epub ahead of print]

Mehta D, Christmas R, Waldmann H, Rosenzweig M. Partial and Transient Modulation of the CD3–T-cell Receptor Complex, Elicited By Low-Dose Regimens of Monoclonal Anti-CD3, is Sufficient to Induce Disease Remission in Non-Obese Diabetic Mice. Immunology. May 2010; 130(1); 103-113.

Keymeulen B, Walter M, Mathieu C, et al. Four-year Metabolic Outcome of a Randomised Controlled CD3-antibody Trial in Recent-onset Type 1 Diabetic Patients Depends on Their Age and Baseline Residual Beta Cell Mass. Diabetologia. April 2010; 53(4); 614-623.

Rosenzweig M, Rosenthal C, Torres V, Vaickus L.  Development of a Quantitative Assay to Measure EBV Viral Load in Patients with Autoimmune Type 1 Diabetes and Healthy Subjects. Journal of Virological Methods. March 2010; 164(1-2): 111-115.

You S, Poulton L, Cobbold S, Liu C-P, Rosenzweig M, et al. Key Role of the GITR/GITRLigand Pathway in the Development of Murine Autoimmune Diabetes: A Potential Therapeutic Target. PLos ONE. November 2009;4(11). (Click here to view this publication.)

Forman D, Ponath P, Mehta D, Ponte J, Snyder J, Rao P, Waldmann H, Rosenzweig M.  Immune privilege and tolerance - therapeutic antibody approaches. In:Little M, ed. Recombinant Antibodies for Immunotherapy;2009:350-372.

Waldmann H, and Cobbold SP. Regulatory T Cells: Context Matters. Immunity. May 22,2009;30:613-615.

You S., Candon S., Kuhn C., Bach J.F. & Chatenoud L. (2008) CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes. Adv Immunol, 100, 13.

Waldmann H, Adams E, and Cobbold SP. Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms. Immuno Rev. 2008;223:361-370.

Rosenthal C, and Rosenzweig M. Advanced science and the art of letting go. European Pharmaceutical Contractor. Summer 2008: 46-48.

Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res. 2005 (Nov. 30).

Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598-2608. (Click here to view this publication.)

Lee I, Wan L, Wells AD, Dorf ME, Ozkaynak E, Hancock WW. Recruitment of Foxp3+ regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med. 2005;201:1037-1044.

Rao PE, Petrone AL, Ponath PP. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-beta. J Immunol. 2005;174:1446-1455.

Winsor-Hines D, Merrill C, O'Mahony M, et al. Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol. 2004;173:4715-4723.

Waldmann H, Cobbold SP, Fairchild P, Adams E. Therapeutic aspects of tolerance. Curr Opin Pharmacol. 2001;1:392-397.

Waldmann H, Cobbold S. Regulating the immune response to transplants: a role for CD4+ regulatory cells? Immunity. 2001;14:399-406.

Waldmann H, Hale G, Cobbold S. Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance. Philos Trans R Soc Lond. 2001;356:659-663.

Waldmann H, Cobbold S. T-cell regulation and transplantation tolerance. Curr Opin Organ Transplantation. 2000;5:83-89.

Waldmann H. Prospects for the application of antibodies in medicine. In: George AJT, Urch Cb, eds. Diagnostic and Therapeutic Antibodies. Totowa, NJ: Humana Press Inc: 2000:63-72. Walker JM, ed. Methods in Molecular Medicine, vol 40.

Gilliland LK, Walsh LA, Frewin MR, et al. Elimination of the immunogenicity of therapeutic antibodies. J Immunol. 1999;162:3663-3671.

Honey K, Cobbold S, Waldmann H. Dominant regulation: a common mechanism of monoclonal antibody induced tolerance? Immunol Res. 1999;20:1-14.

Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol. 1998;16:619-644.

Wise MP, Bemelman F, Cobbold SP, Waldmann H. Cutting edge: linked suppression of skin graft rejection can operate through indirect recognition. J Immunol. 1998;161:5813-5816.

Marshall SE, Cobbold SP, Davies JD, Martin GM, Phillips JM, Waldmann H. Tolerance and suppression in a primed immune system. Transplantation. 1996;62:1614-1621.

Waldmann H, Cobbold S. Monoclonal antibodies for the induction of transplantation tolerance. Curr Opin Immunol. 1993;5:753-758.

Waldmann H, Cobbold S. The use of monoclonal antibodies to achieve immunological tolerance. Immunol Today. 1993;14:247-251.

Qin S, Wise M, Cobbold SP, et al. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol. 1990;20:2737-2745.